These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 18390631)

  • 1. Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study.
    von Plessen C; Strand TE; Wentzel-Larsen T; Omenaas E; Wilking N; Sundstrøm S; Sörenson S
    Thorax; 2008 Oct; 63(10):866-71. PubMed ID: 18390631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
    Ng R; Hasan B; Mittmann N; Florescu M; Shepherd FA; Ding K; Butts CA; Cormier Y; Darling G; Goss GD; Inculet R; Seymour L; Winton TL; Evans WK; Leighl NB; ; ;
    J Clin Oncol; 2007 Jun; 25(16):2256-61. PubMed ID: 17538170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
    Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
    J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
    Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
    J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer.
    d'Amato TA; Ashrafi AS; Schuchert MJ; Alshehab DS; Seely AJ; Shamji FM; Maziak DE; Sundaresan SR; Ferson PF; Luketich JD; Landreneau RJ
    Ann Thorac Surg; 2009 Oct; 88(4):1079-85. PubMed ID: 19766784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
    Grossi F; Aita M; Defferrari C; Rosetti F; Brianti A; Fasola G; Vinante O; Pronzato P; Pappagallo G
    Oncologist; 2009 May; 14(5):497-510. PubMed ID: 19423674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of potential interaction between vinorelbine and clarithromycin.
    Yano R; Tani D; Watanabe K; Tsukamoto H; Igarashi T; Nakamura T; Masada M
    Ann Pharmacother; 2009 Mar; 43(3):453-8. PubMed ID: 19261952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.
    Luciani A; Bertuzzi C; Ascione G; Di Gennaro E; Bozzoni S; Zonato S; Ferrari D; Foa P
    Lung Cancer; 2009 Oct; 66(1):94-6. PubMed ID: 19171407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional differences in treatment and outcome in non-small cell lung cancer: a population-based study (Sweden).
    Myrdal G; Lamberg K; Lambe M; Ståhle E; Wagenius G; Holmberg L
    Lung Cancer; 2009 Jan; 63(1):16-22. PubMed ID: 18571760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.